HIGHLIGHTS
- who: Lioba Schu00f6nfeld from the (UNIVERSITY) have published the research work: ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia, in the Journal: (JOURNAL) of 28/07/2022
- what: To advance the understanding of the role of mutations in addition to BCR::ABL1, the study aimed to evaluate their prevalence and dynamics in a large, well-characterized patient population in an ongoing prospective clinical trial. This study provides a prospective analysis of leukemia-associated gene mutations in newly diagnosed CML patients treated within a controlled clinical trial. The study provides novel . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.